Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia. Market research commissioned by Acasti* suggests there is an important market need for an effective, safe and well-absorbing omega-3 therapeutic with a positive impact on the major lipids associated with cardiovascular disease risk. Since August 2008, Acasti is focused on addressing this important unmet market need.
Acasti’s lead product candidate is CaPre® (omega-3 phospholipid), which the company is developing in a Phase 3 program for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL). Acasti believes the potential exists to expand CaPre’s indication to treat individuals with high levels of triglycerides (200 – 499 mg/dL), which may require additional comparative studies or outcome trials, assuming positive outcome study data in the next two years from two competitors. In addition, Acasti may seek to identify new potential indications for CaPre that may be appropriate for future studies and pipeline expansion.
Since 2008, Acasti Pharma’s scientists have focused on the research and development of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of cardiometabolic diseases.
Acasti’s lead drug candidate, CaPre, is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are present as a combination of phospholipid esters and free fatty acids.
Acasti’s growing global patent portfolio encompasses CaPre and its composition until the last of its patents expire in 2031. Acasti currently holds numerous composition of matter and method of use patents in various jurisdictions around the world including in the U.S., China, Japan, Taiwan and Australia, and we have numerous additional patents pending.